May 4, 2023 09:00 AM EDTUpdated 03:48 PM

Reverse mergers say hey as biotechs trade low, hunt for alternatives and launch few IPOs

Kyle LaHucik

Senior Reporter

The reverse merger announced Wednesday morning between Magenta Therapeutics and privately-held Dianthus Therapeutics, which will take over the Nasdaq spot and push forward its complement …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Reverse mergers say hey as biotechs trade low, hunt for alternatives and launch few IPOs

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Executive Director, Marketing

Celldex Therapeutics

Hampton, NJ, USA

New fund will pressure flailing biotechs, as investor frustration boils over

FDA chief Makary talks expediting drug approvals, RIFs and the abortion pill

Akeso shares new data suggesting it can beat Keytruda on survival, wins China approval

Caribou lays off 32% of staff, cuts lupus cell therapy program before first patient

AbbVie commits $10B to expand US footprint with the threat of tariffs ahead

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

Re­verse merg­ers say hey as biotechs trade low, hunt for al­ter­na­tives and launch few IPOs

Senior Reporter

Sign up to read this article for free.

Celldex Therapeutics

Hampton, NJ, USA

Reverse mergers say hey as biotechs trade low, hunt for alternatives and launch few IPOs